Skip to content
PubMed This is a summary of 49 peer-reviewed journal articles Updated
Hematology

Kaposiform Lymphangiomatosis: A Patient Guide

At a Glance

Kaposiform lymphangiomatosis is a rare disease of abnormal lymphatic vessels that can affect the chest, lungs, and bones, causing breathing and bleeding problems. Treatment often combines specialist care with targeted medicines such as sirolimus or trametinib.

Kaposiform lymphangiomatosis (KLA) is a rare and complex condition that affects the lymphatic system, the network of vessels responsible for maintaining fluid balance and supporting the immune system. Unlike more common lymphatic marks, KLA is characterized by the presence of specialized spindle cells that cause the lymphatic vessels to grow and behave in an aggressive, disorganized manner. This condition is often described as a multisystem disease because it tends to involve several parts of the body simultaneously, particularly the chest cavity, lungs, and bones [1][2].

The behavior of KLA is largely driven by a specific genetic change known as an NRAS mutation. This is a somatic mutation, meaning it is a change that occurred in the affected tissue during development rather than being inherited from a parent in a way that passes down. This mutation acts like a permanent “on” switch, signaling the lymphatic cells to grow and spread abnormally. In the chest, this can lead to the buildup of fluid around the lungs and heart, which often impacts breathing. Additionally, KLA can interfere with how the blood clots—a process called consumptive coagulopathy—where the abnormal vessels “use up” the body’s platelets and clotting proteins, increasing the risk of bleeding [3][4].

Managing KLA has been transformed in recent years by the development of targeted therapies. Because researchers now understand the genetic pathways involved, doctors can use medications such as mTOR inhibitors (sirolimus) and MEK inhibitors (trametinib) to specifically block the signals driving the disease. These treatments aim to stabilize the lymphatic vessels, improve blood counts, and reduce fluid accumulation. Because the disease affects so many different systems, care is best managed by a multidisciplinary vascular anomalies team—a group of specialists including hematologists, radiologists, and pulmonologists who coordinate every aspect of treatment [5][6].

While KLA is a serious and life-altering diagnosis, the shift toward precision medicine means that care is more personalized, though responses still vary. Living with KLA requires ongoing vigilance and long-term monitoring, but the goal of modern treatment is to manage the disease effectively so that patients can focus on their daily lives. You are not alone in this journey; you are supported by a dedicated community of experts and families committed to navigating this complex condition together [7][8].

Common questions in this guide

What is kaposiform lymphangiomatosis?
Kaposiform lymphangiomatosis (KLA) is a rare disorder of the lymphatic system, which helps manage body fluid and supports immunity. Abnormal lymphatic vessels and specialized cells can affect several body systems, especially the chest, lungs, and bones.
Is KLA caused by an inherited gene?
KLA is linked to a somatic NRAS mutation in affected tissue. Somatic means the change develops in the tissue during development and is not inherited from a parent in a way that is passed to children.
What problems can KLA cause?
KLA can cause fluid to collect around the lungs and heart, which may affect breathing. It can also cause consumptive coagulopathy, in which abnormal vessels use up platelets and clotting proteins and increase bleeding risk.
What medicines are used to treat KLA?
Doctors may use targeted medicines such as sirolimus, an mTOR inhibitor, or trametinib, a MEK inhibitor. These treatments aim to calm abnormal lymphatic growth, improve blood counts, and reduce fluid buildup, but response varies from person to person.
What specialists care for someone with KLA?
KLA is best managed by a multidisciplinary vascular anomalies team that coordinates care across the disease’s different effects. The team may include hematologists, radiologists, and pulmonologists, and a specialized vascular anomalies center may provide an additional review.
When should someone with KLA seek urgent help?
Seek emergency help for respiratory distress or uncontrolled bleeding, because KLA can affect breathing and blood clotting. Ask the care team for a written emergency plan and track daily symptoms that may signal a change.

Get notified when new evidence is published on Kaposiform lymphangiomatosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (8)
  1. 1

    Kaposiform Lymphangiomatosis: Pathologic Aspects in 43 Patients.

    Perez-Atayde AR, Debelenko L, Al-Ibraheemi A, et al.

    The American journal of surgical pathology 2022; (46(7)):963-976 doi:10.1097/PAS.0000000000001898.

    PMID: 35385405
  2. 2

    Potential biomarkers of kaposiform lymphangiomatosis.

    Ozeki M, Nozawa A, Kawamoto N, et al.

    Pediatric blood & cancer 2019; (66(9)):e27878 doi:10.1002/pbc.27878.

    PMID: 31207041
  3. 3

    A somatic activating NRAS variant associated with kaposiform lymphangiomatosis.

    Barclay SF, Inman KW, Luks VL, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2019; (21(7)):1517-1524 doi:10.1038/s41436-018-0390-0.

    PMID: 30542204
  4. 4

    Kaposiform lymphangiomatosis and kaposiform hemangioendothelioma: similarities and differences.

    Ji Y, Chen S, Peng S, et al.

    Orphanet journal of rare diseases 2019; (14(1)):165 doi:10.1186/s13023-019-1147-9.

    PMID: 31277673
  5. 5

    MEK Inhibition Reduces Vascular Malformations and Gene Dysregulation in NRASQ61R Human Endothelial Cells.

    Alharbi S, Wagner A, Merkle S, et al.

    Pediatric blood & cancer 2026; (73(3)):e70002 doi:10.1002/1545-5017.70002.

    PMID: 41496696
  6. 6

    Resolution of Refractory Chylous Effusions With Targeted MEK Inhibition in NRAS Q61R-Driven Kaposiform Lymphangiomatosis: A Case Report.

    Brown G, McNab S, Keogh S, et al.

    Case reports in pediatrics 2026; (2026()):7037459 doi:10.1155/crpe/7037459.

    PMID: 42639465
  7. 7

    Multidisciplinary guidelines for initial evaluation of complicated lymphatic anomalies-expert opinion consensus.

    Iacobas I, Adams DM, Pimpalwar S, et al.

    Pediatric blood & cancer 2020; (67(1)):e28036 doi:10.1002/pbc.28036.

    PMID: 31617676
  8. 8

    Kaposiform lymphangiomatosis: Diagnosis, pathogenesis, and treatment.

    McDaniel CG, Adams DM, Steele KE, et al.

    Pediatric blood & cancer 2023; (70(4)):e30219 doi:10.1002/pbc.30219.

    PMID: 36683202

This page is for informational purposes only and does not constitute medical advice about kaposiform lymphangiomatosis. Your vascular anomalies team should guide decisions about symptoms, bleeding or breathing emergencies, and treatment for you or your child.